AIG1
Overview
AIG1 (Androgen-Induced Gene 1) encodes a transmembrane protein first identified as androgen-regulated. In cancer genomics, AIG1 has emerged as a structural rearrangement partner in adenoid cystic carcinoma (ACC), where it serves as a novel 5’-fusion partner for NFIB in tumors lacking the canonical MYB-NFIB translocation.
Alterations observed in the corpus
- Novel 5’-NFIB fusion partner identified in t(6;9)-positive/MYB-NFIB-negative adenoid cystic carcinoma tumors PMID:26631609
Cancer types (linked)
- Adenoid cystic carcinoma: identified as a recurrent NFIB fusion partner in MYB-NFIB-negative tumors PMID:26631609
Co-occurrence and mutual exclusivity
- AIG1-NFIB fusions occur in t(6;9)-positive tumors that lack the canonical MYB-NFIB rearrangement; co-occurs with other novel 5’-NFIB partners (XRCC4, NKAIN2, PTPRD) as part of a broader NFIB-fusion positive subclass PMID:26631609
Therapeutic relevance
- No direct therapeutic agents targeting AIG1 are established; the broader MYB-family transcriptional activation context (shared with MYB-NFIB and MYBL1-NFIB fusions) may be relevant to therapeutic strategies targeting MYB-family activity PMID:26631609
Open questions
- The functional consequence of the AIG1-NFIB fusion on NFIB transcriptional activity and ACC oncogenesis has not been experimentally validated PMID:26631609
Sources
This page was processed by crosslinker on 2026-05-14.